Results 151 to 160 of about 79,188 (304)
Distinct purpuric lesions in patients with dermatomyositis
Sung Kyung Cho, BA +2 more
doaj +1 more source
Among 135 cases of post‐liver transplant HHV8 disease (4 from NSW), presentations varied, and mortality was high (44%). Donor screening was rare, and donor‐derived infection was suspected in 33%. Survival improved with mTORi, reduced immunosuppression, chemotherapy, and, for non‐KS disease, donor screening. ABSTRACT Background Human herpesvirus 8 (HHV8)
Karen M. J. Waller +12 more
wiley +1 more source
Acral palpable purpura in a patient with nephritis and shortness of breath. [PDF]
Gillespie Y, Hammond AM, Motaparthi K.
europepmc +1 more source
Abstract Background Thrombocytopenia arises from heterogeneous inherited and acquired disorders, and identifying the underlying platelet clearance mechanisms remains challenging. Platelet desialylation, characterised by loss of sialic acid and consequent exposure of terminal β‐galactose residues recognised by the Ashwell–Morell receptor, represents an ...
Karen Nogueira Chinoca Ziza +14 more
wiley +1 more source
Immunoglobulin A Vasculitis-Associated Ileoileal Intussusception in an Adult Male: Case Report. [PDF]
Sawhney P, Frost P, Stueve P, Boccio E.
europepmc +1 more source
Delayed Recognition of Thrombotic Thrombocytopenic Purpura Following Platelet Transfusion: A Clinical Pitfall. [PDF]
Al-Dawoudi A +4 more
europepmc +1 more source
Abstract Background The increasing diversity of blood donor populations has created new challenges for transfusion services worldwide. The identification of donors lacking relevant high‐prevalence antigens is becoming increasingly important to ensure compatible blood products for alloimmunized patients and to support the development of rare donor ...
Sarah Petermann +7 more
wiley +1 more source
Beyond Eschar: Unusual Skin Findings in Scrub Typhus. [PDF]
Biswas T +7 more
europepmc +1 more source
Abstract Background and Objectives Amotosalen/ultraviolet A light (A/UVA) pathogen‐reduced platelets and plasma have been approved for clinical use in Europe since 2003 and 2006, respectively. Cross‐sectional safety haemovigilance (HV) studies have been conducted in 29 hospitals in 15 European countries since 2003. This report describes the most recent
Magdalena Łętowska +14 more
wiley +1 more source

